MYTELASE
LOE ApproachingNDAORALTABLET
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYTELASE is an oral small-molecule tablet approved in 1956 by Sanofi for an undisclosed indication. The mechanism of action and specific therapeutic use are not documented in available data.
LOE Approaching
Product approaching loss of exclusivity with minimal current linked job activity; commercial teams are likely in transition or maintenance mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MYTELASE currently has zero linked job postings, reflecting its mature stage and approaching loss of exclusivity. Career opportunities are limited and likely focused on legacy product management or post-LOE transition roles rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on MYTELASE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.